Aligos Therapeutics, Inc.ALGSNASDAQ
LOADING
|||
Key Metrics
As of 2024• vs 2023
Per Share
Revenue/Share
$0.63+0.9%
Net Income/Share
$-20.94-494.2%
Operating CF/Share
$-12.89-305.8%
Free CF/Share
$-12.91-306.4%
Cash/Share
$9.09+66.6%
Book Value/Share
$-4.62-224.9%
Tangible Book/Share
$-4.62-224.9%
Equity/Share
$-4.62-224.9%
Interest Debt/Share
$1.34+198.6%
Valuation
Market Cap
$249.58M-39.6%
Enterprise Value
P/E Ratio$220.96M-23.4%
-1.90+59.6%
P/S Ratio63.27+137.9%
P/OCF Ratio
-3.09+40.9%
P/FCF Ratio
P/B Ratio-3.09+40.9%
-8.61-292.1%
P/TB Ratio
EV/Sales-8.61-292.1%
56.01+201.7%
EV/EBITDA
-2.55+24.7%
Profitability
Earnings Yield-52.57%-147.6%
FCF Yield-32.40%-69.3%
ROE452.87%+575.6%
ROIC-172.06%-155.5%
Return on Tangible Assets-187.19%-223.5%
Capital Allocation
CapEx/OCF
-0.16%-569.4%
CapEx/Revenue
3.30%+2593.3%
CapEx/Depreciation
0.05+700.9%
SBC/Revenue
214.25%+163.0%
Balance Sheet
Debt/Equity-0.29-339.0%
Debt/Assets0.12+62.5%
Net Debt/EBITDA
Current Ratio0.33-77.4%
2.86-51.6%
Interest Coverage0.00x
Income Quality0.62-31.7%
Efficiency
Days Sales Outstanding
0 days
Days Payables Outstanding
0 days
Days Inventory
0 days
Receivables Turnover
0.00x
Payables Turnover
0.00x
Inventory Turnover
0.00x
Special Valuations
Graham Number
--
Graham Net-Net
$-6.72-319.3%